Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI

References

• Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205–2241
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Working group on high on-treatment platelet reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919–933
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: Current status and future directions. Thromb Haemost 2009;102:7–14
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O Connell JR, Bliden KPm Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Gurbel PA, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849–857
   PubMed Web of Science ®Google Scholar
• Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, Hwang SJ, Bliden KP, Kwak CH, Hwang JY, et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 2011;4:585–594
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354–362
   PubMed Web of Science ®Google Scholar
• Ono T, Kaikita K, Hokimoto S, Iwashita S, Yamamoto K, Miyazaki Y, Horio E, Sato K, Tsujita K, Abe T, et al. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thromb Res 2011;128:130–136
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754–762
   PubMed Web of Science ®Google Scholar
• Jin HY, Yang TH, Kim DI, Chung SR, Seo JS, Jang JS, Kim DK, Kim KH, Seol SH, Nam CW, et al. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. Int J Cardiol 2012 [epub ahead of print]
   Google Scholar
• Johnson A, Dovlatova N, Heptinstall S. Multiple electrode aggregometry and P2Y12 antagonists. Thromb Haemost 2008;99:1127–1129
   PubMed Web of Science ®Google Scholar
• Gremmel T, Kopp CW, Moertl D, Seidinger D, Koppensteiner R, Panzer S, Mannhalter C, Steiner S. Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. Thromb Res 2012;129:616–622
   PubMed Web of Science ®Google Scholar
• Ko YG, Suh JW, Kim BH, Lee CJ, Kim JS, Choi D, Hong MK, Seo MK,Youn TJ, Chae IH, et al. Comparison of 2 point of care platelet function tests, VerifyNow assay and multiple electrode platelet aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J 2011;161:383–390
   PubMed Web of Science ®Google Scholar
• Lordkipanidze M, Pharand C, Nquyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008;29:2877–2885
   PubMed Web of Science ®Google Scholar
• Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007;5:1839–1847
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Parlk E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010;8:482–488
   PubMed Web of Science ®Google Scholar
• Paniccia R, Antonucci E, Maggini N, Miranda M, Gori AM, Marcucci R, Giusti B, Balzi D, Prisco D, Abbate R. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010;104:287–292
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: The PEGASUS-PCI study. J Thromb Haemost 2012;10:529–542
   PubMed Web of Science ®Google Scholar
• Park Y, Jeong YH, Kim IS, Yun SE, Kwon TJ, Hwang SJ, Kwak CH, Hwang JY. The concordance and correlation of measurements by multiple electrode and light transmittance aggregometries based on the pre-defined cutoffs of high and low on-treatment platelet reactivity. Platelets 2012;23:290–298
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, Saut N, Faille D, Lambert M, Juhan-Vague I, Bonnet JL, et al. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008;101:1088–1093
   PubMed Web of Science ®Google Scholar
• Jaitner J, Steqherr J, Morath T, Braun S, Bernlochner I, Schomig A, Kastrati A, Sibbing D. Stability of the high on treatment platelet reactivity phenotype over time in clopidogrel treated patients. Thromb Haemost 2011;105:107–112
   PubMed Web of Science ®Google Scholar
• Kim IS, Jeong YH, Kang MK, Koh JS, Park Y, Hwang SJ, Kwak CH, Hwang JY, Kim S. Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. J Thromb Thrombolysis 2010;30:486–495
   PubMed Web of Science ®Google Scholar
• Gaqlia MA Jr, Torquson R, Pakala R, Xue Z, Sardi G, Mahmoudi M, Suddath WO, Kent KM, Satler LF, Pichard AD, et al. Relation of body mass index to on treatment (clopidogrel + aspirin) platelet reactivity. Am J Cardiol 2011;108:766–771
   Google Scholar
• Gori AM, Marcucci R, Paniccia R, Giusti B, Fedi S, Antonucci E, Buonamici P, Antoniucci D, Gensini GF, Abbate R. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost 2008;100:1136–1145
   PubMed Web of Science ®Google Scholar
• Patti G, Nusca A, Mangiacapra F, Gatto L, D’Ambrosio A, Di Sciascio G. Potint-of care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52:1128–1133
   PubMed Web of Science ®Google Scholar
• Jeong YH, Cho JH, Kang MK, Koh JS, Kim IS, Park Y, Hwang SJ, Kwak CH, Hwang JY. Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. Thromb Res 2010;126:334–338
   Web of Science ®Google Scholar
• Paniccia R, Antonucci E, Maggini N, Miranda M, Romano E, Gori AM, Marcucci R, Prisco D, Abbate R. Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: A methodological study. Ther Drug Monit 2011;33:94–98
   PubMedGoogle Scholar
• Zhang HZ, Yu LH, Kim MH. Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: A comparison between citrate and hirudin. Platelets 2013;24:339--347
   PubMed Web of Science ®Google Scholar